Thursday 18 February

Understanding and combating obviousness rejections under 35 U.S.C. 103 before the USPTO

When and where

Date and time

Start: Thursday 18 February 2021, 02:00 PM

End: Thursday 18 February 2021, 03:00 PM

Event Overview

Obviousness rejections are ubiquitous when dealing with the USPTO. Although they are commonplace in examination, it can be difficult to clearly identify the Examiner’s concerns reflected in the rejection and to plot a path to patentable claims. Our discussion will focus on these rejections with suggestions for overcoming them and working with your Examiner to find a way forward.




Loren Hulse, Holland & Hart

Loren Hulse, Holland & Hart

As a practitioner, Loren has developed, managed, and protected both large and small domestic and foreign patent and trademark portfolios. His wide-ranging biotech and pharmaceutical experience includes advising clients how to protect small molecule and peptide drugs, methods of treatment, genetic constructs and therapies, nucleotide analogs, and RNA related drug technologies. He has also counseled clients developing medical devices such as optically-guided feeding tubes, injectors, diagnostic kits, catheters, and cardiac assist devices. In the chemical arena, Loren’s experience includes assisting clients to protect solid oxide fuel cell technologies, ionically-conductive membrane applications, and syngas production techniques.

The event has been added to your basket:

Understanding and combating obviousness rejections under 35 U.S.C. 103 before the USPTO

Proceed to basket

Shopping Basket

No products in the cart.

Are you a CIPA member?

Sign in to your account to register for the event

Forgotten password?

If you are not yet registered or a member of CIPA, please register here

Skip to content